Recently, another study by Wallentin et al. investigated the prognostic relevance of GDF-15 in relation to randomized anti-platelet treatment and an interventional management strategy in the NSTE-ACS subgroup of the Platelet Inhibition and Patient Outcomes (PLATO) trial.[35] In that study, GDF-15 was a significant predictor of cardiovascular death, myocardial infarction, and stroke in patients managed both conservative and invasively. Here, GDF15 is linked to myocardial infarction.